C4X Discovery Holdings PLC C4XD and HitGen to collaborate in inflammation (4791D)
20 October 2022 - 5:00PM
UK Regulatory
TIDMC4XD
RNS Number : 4791D
C4X Discovery Holdings PLC
20 October 2022
C4XD and HitGen to collaborate in inflammation hit
identification project
Initial project with option to expand collaboration on
successful outputs
20 October 2022 - C4X Discovery Holdings plc ("C4XD", AIM:
C4XD), a pioneering Drug Discovery company, and Shanghai Stock
Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), a
world leader in the development and application of DNA-encoded
library (DEL) technology, today announce a research collaboration
project to identify novel, small molecule hits against an
inflammatory target for further C4XD development.
The aim of the project is to augment C4XD's growing pipeline of
small molecule inflammatory disease candidates for pre-clinical
development and out-licensing to the pharmaceutical industry. In
this initial collaboration, C4XD and HitGen have together developed
an approach for HitGen to apply its DEL screening technology
platform to identify hits against a commercially valuable target
for inflammatory diseases. If successful, C4XD will then apply its
molecule design Conformetrix technology to translate these hits
into suitable starting points for a small molecule programme, which
can then be progressed through C4XD's rigorous Drug Discovery
process. C4XD has the option to extend the collaboration with
HitGen during this Drug Discovery phase to leverage HitGen's
growing R&D capabilities.
Dr. Clive Dix, CEO of C4XD, said : "In line with our strategy to
collaborate with innovative technology partners, C4XD extensively
evaluates the small molecule discovery landscape and builds
relationships with high potential complementary companies. We
believe this collaboration with HitGen gives us access to a
world-leading screening technology, which perfectly complements
both our Drug Discovery expertise and Conformetrix technology and
could enable C4XD to unlock a highly challenging target in
inflammation . We are looking forward to working with their team
and continuing to build on this exciting relationship."
Dr. Jin Li, Chairman of the Board and Chief Executive Officer of
HitGen, said: "C4XD is a highly innovative company and has
developed some very high-value assets using their proprietary
Conformetrix technology. Combining their expertise with HitGen's
world leading DNA-encoded library technology platform, we look
forward to identifying good starting points for further development
into valuable leads for the inflammatory target. We hope the
collaboration could eventually turn into a strong partnership to
deliver a number of solutions for highly unmet medical needs."
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world leading medicines, which
are developed by our partners for the benefit of patients. We have
a highly valuable and differentiated approach to Drug Discovery
through our enhanced DNA-based target identification and candidate
molecule design capabilities, generating small molecule drug
candidates across multiple disease areas including inflammation,
oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early-stage novel
target opportunities to late-stage Drug Discovery programmes ready
for out-licensing to partners and we have two commercially
partnered programmes with one candidate in clinical
development.
We collaborate with leading pharmaceutical and life sciences
companies to enrich our expertise and take our assets through
pre-clinical and clinical development. Through early-stage
revenue-generating licensing deals, we realise returns from our
high value pre-clinical assets which are reinvested to maximise the
value of our Drug Discovery portfolio. For further information, see
our website: www.C4XDiscovery.com
About HitGen Inc.
HitGen Inc. (SSE: 688222.SH), is a drug discovery research
company with headquarters in Chengdu, China, and subsidiaries in
Cambridge, UK and Houston, USA. HitGen has established leading
technology platforms to enable the discovery and optimization of
small molecules and nucleic acid drugs. Our key technology
platforms include DNA-encoded library technology (DEL),
fragment-based drug discovery and structure-based drug design
technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide
technology (STO), and targeted protein degradation technology
(TPD). Through our diverse and flexible business models, we have
built up collaboration partnership with several hundred
biopharmaceutical research organizations worldwide. HitGen has
multiple programmes from early discovery to clinical trial
stage.
For more information, please call +86-28-85197385,
+1-508-840-9646 or visit www.hitgen.com .
For media inquiries: media@hitgen.com
For investor inquiries: investors@hitgen.com
For business development: bd@hitgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAPENFDFAFFA
(END) Dow Jones Newswires
October 20, 2022 02:00 ET (06:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024